Guangdong Provincial People's Hospital

🇨🇳China
Ownership
Private
Established
1946-01-01
Employees
-
Market Cap
-
Website
http://www.gdghospital.org.cn
prnewswire.com
·

Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2

Innovent Biologics presents updated Phase 2 trial results of Dupert® (fulzerasib), a KRAS G12C inhibitor for advanced NSCLC at WCLC 2024. Fulzerasib showed 49.1% ORR and 90.5% DCR, with a median PFS of 9.7 months. It was well-tolerated, with no additional safety signals. Dupert® was approved by NMPA in August 2024 for KRAS G12C mutated NSCLC patients.
© Copyright 2024. All Rights Reserved by MedPath